Bill

Bill > HB2218


KS HB2218

KS HB2218
Amending the definition of "psilocybin" in the uniform controlled substances act to exclude the pharmaceutical composition of crystalline polymorph psilocybin and adding crystalline polymorph psilocybin to schedule IV of the uniformed controlled substance act.


summary

Introduced
02/03/2025
In Committee
01/28/2026
Crossed Over
Passed
Dead

Introduced Session

2025-2026 Regular Session

Bill Summary

AN ACT concerning the uniform controlled substances act; defining psilocybin to exclude the pharmaceutical composition of crystalline polymorph psilocybin; adding crystalline polymorph psilocybin to schedule IV; amending K.S.A. 2024 2025 Supp. 65-4101 and 65-4111 and repealing the existing sections.

AI Summary

This bill amends the Uniform Controlled Substances Act by clarifying the definition of "psilocybin" to specifically exclude its pharmaceutical composition when it is a crystalline polymorph, such as the drug product known as COMP 360 or any other trade name approved by the U.S. Food and Drug Administration (FDA). Additionally, this pharmaceutical composition of crystalline polymorph psilocybin will be added to Schedule IV of the Uniform Controlled Substances Act, which lists substances with a lower potential for abuse than those in Schedule III and a currently accepted medical use in treatment in the United States. The bill outlines a process where, upon FDA approval of this specific psilocybin composition, the Attorney General will certify this approval to the Secretary of State, who will then publish it in the Kansas Register, making these changes effective.

Committee Categories

Health and Social Services

Sponsors (0)

No sponsors listed

Other Sponsors (1)

Health and Human Services (House)

Last Action

House Stricken from Calendar by Rule 1507 (on 02/19/2026)

bill text


bill summary

Loading...

bill summary

Loading...
Loading...